<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210214050354N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-26</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the efficacy of traditional method and modified technique for Botulinum injection in overactive bladder</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of urodynamic results of Minimistic intra-detrusor Botulinum injection and traditional technique during bladder storage phase in patients with idiopathic over active bladder</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>78</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54300</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Balance block randomization method :
-In the present study we used Block randomization that is a commonly used technique in clinical trial design to reduce bias and achieve balance in the allocation of participants to treatment arms, especially when the sample size is small.
The basic idea of block randomization is to divide potential patients into m blocks of size 2n, randomize each block such that n patients are allocated to A and n to B. then choose the blocks randomly. This method ensures equal treatment allocation within each block if the complete block is used.

-We consist a 3 columns table in Excel . First one is  patients' numbers in order to enter the study . Second one is for their randomized group of intervention ( A or B ) and the last one is for the codes we will give to patients to make them  and the analyzers blind about types of interventions , Blinding description: 1)Patients 
2)Observers who evaluate patients 4-6 weeks after procedures by urodynamic
3) Methodologist who analyzes the final data.</study_design>
      <phase>3</phase>
      <hc_freetext>Idiopathic overactive bladder.</hc_freetext>
      <i_freetext>Intervention 1: Control group: As traditional method , spinal or general anesthesia is used. Patients will be hospitalized at least for one day after procedure . In each injection, 0.5 cc Botox are applied by injection at 20 sites of bladder detrusor muscle, mostly in posterior and lateral walls, using Cystoscope .  A 500 IU Dysport vial is diluted in 10 cc normal saline for injections. Intervention 2: Intervention group:  in Minimistic or the modified method , an oral or IV sedative will be used before procedure. Then 100 cc Lidocaine 2% will be injected in bladder using a 14F Foley catheter. After 15-20 minutes a diluted 500 IU Dysport will be injected at 5-6 main sites, mostly in posterior and lateral walls of bladder, using Cystoscope.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data including age , sex and all urodynamic study results can be shared  after eliminating  private information of the patients.

When:
September 2022

To whom:
Academic researchers

Conditions:
1)For research only 
2)A researcher or an organization who aim to use the results of the present study must precisely refer to this RCT in details.

Where to obtain:
Email address : n.soleimanifard@gmail.com

How to obtain:
1)Evaluating the qualification of the applicants
2)Ensuring that the precise title and information of the current study will be mentioned in their studies. 
3)After publishing the results as an article, all researchers can benefit from the published manuscript. We also will provide the pdf of the article should a researcher ask at later stages.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Emami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hasheminejad kidney center , Valinezhad St, Vanak Sq, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۹۶۹۷۱۴۷۱۳</zip>
        <telephone>+98 21 8116 1532</telephone>
        <email>emami59658@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Emami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hasheminejad kidney center , Valinezhad St, Vanak Sq, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۹۶۹۷۱۴۷۱۳</zip>
        <telephone>+98 21 8116 1532</telephone>
        <email>emami59658@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Idiopathic overactive bladders resistant to anticholinergic drugs taking at least four weeks.
Anticholinergic medication intolerance due to side effects
Anticholinergic contraindications</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Neurogenic bladder due to CVA , Multiple sclerosis, Spinal cord injury ,  head trauma , Parkinson , disc herniations .
Severe bladder outlet obstruction
Recurrent UTI
Urinary tract anomalies
Previous bladder surgery
History of pelvic radiation
History of pelvic malignancies
Pregnancy
Age &lt; 18 years old
Male</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N00-N99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>disease of the genitourinary system</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: As traditional method , spinal or general anesthesia is used. Patients will be hospitalized at least for one day after procedure . In each injection, 0.5 cc Botox are applied by injection at 20 sites of bladder detrusor muscle, mostly in posterior and lateral walls, using Cystoscope .  A 500 IU Dysport vial is diluted in 10 cc normal saline for injections.</i_keyword>
      <i_keyword>Intervention group:  in Minimistic or the modified method , an oral or IV sedative will be used before procedure. Then 100 cc Lidocaine 2% will be injected in bladder using a 14F Foley catheter. After 15-20 minutes a diluted 500 IU Dysport will be injected at 5-6 main sites, mostly in posterior and lateral walls of bladder, using Cystoscope.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Comparison of urodynamic results of Minimistic intra-detrusor botulinum injection and traditional technique during bladder storage phase in patients with idiopathic over active bladder. Timepoint: Urodynamic study before Botulinum injection and after 4-6 weeks post injection. Method of measurement: Urodynamic study.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Assessing the mean of maximum detrusor pressure in filling phase in traditional method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Assessing the mean of maximum detrusor pressure in filling phase in Minimistic method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Comparison of the mean of maximum detrusor pressure in filling phase in both Minimistic and traditional methods. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Assessing the mean of each detrusor over-activity duration in traditional method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Assessing the mean of each detrusor over-activity  duration in Minimistic method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Comparison of the mean of each detrusor over-activity duration in both Minimistic and traditional methods. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Assessing the mean of bladder capacity in beginning of each detrusor over-activity  in traditional method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Assessing the mean of bladder capacity in beginning of each detrusor over-activity  in Minimistic method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Comparison of the mean of bladder capacity in beginning of each detrusor over-activity in both traditional and Minimistic  methods. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Assessing the mean of functional bladder capacity in traditional method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Assessing the mean of  functional bladder capacity in Minimistic method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Comparison of the mean of functional bladder capacity in both traditional and Minimistic methods. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Assessing the mean of maximum bladder capacity in traditional method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Assessing the mean of maximum bladder capacity in Minimistic method. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
      <sec_outcome>Comparison of the mean of maximum bladder capacity in both traditional and Minimistic methods. Timepoint: Before intervention and  4-6 weeks after Botox injection. Method of measurement: Urodynamic study.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-27</approval_date>
        <contact_name>Ethics committee of Iran university of medical science</contact_name>
        <contact_address>Hasheminezhad kidney center Hospital , Valinezhad street , Valiasr BLVD, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
